INTERNATIONAL CONGRESS OF
CancerGenetics
Novel Targets for Treatment of Advanced Endometrial Cancer: literature review
-
Romina zamanikia,1,* Vahid akbarinezhad,2
1. Department of Theriogenology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
2. Department of Theriogenology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
- Introduction: Endometrial cancer is one of the most common gynecologic cancers, with limited treatment options for advanced stages. While traditional therapies like surgery, chemotherapy, and radiation provide some benefits, they often fall short in improving survival rates for advanced and recurrent cases. Recent advances in understanding the molecular mechanisms driving endometrial cancer have led to the identification of novel therapeutic targets, offering hope for more effective treatment strategies.
- Methods: Adapted from authoritative articles such as Pubmed, Google scholar and so on.
- Results: This literature review examines emerging molecular targets, focusing on pathways such as PI3K/AKT/mTOR, immune checkpoint inhibition, and mismatch repair deficiency (dMMR). Inhibition of the PI3K/AKT/mTOR pathway, frequently mutated in endometrial cancer, has demonstrated promise in clinical trials. Immunotherapies, particularly PD-1/PD-L1 inhibitors, have shown efficacy in patients with dMMR tumors. Other targets, including FGFR inhibitors, HER2/neu mutations, and ARID1A mutations, are under investigation with promising early results.
- Conclusion: The development of targeted therapies based on specific molecular alterations has the potential to transform treatment for advanced endometrial cancer. Early clinical data show encouraging outcomes, but further research is needed to optimize these therapies and explore combination approaches to improve survival and quality of life for patients with advanced disease.
- Keywords: Endometrial cancer, targeted therapy, immune checkpoint inhibitors, HER2, PI3K/AKT/mTOR
